In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1- oxopropyl)-maytansine against CD56+ multiple myeloma cells

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4629-4636

  Tassone, Pierfrancesco ^a,b   Gozzini, Antonella ^a   Goldmacher, Victor ^c   Shammas, Masood A ^a   Whiteman, Kathleen R ^c   Carrasco, Daniel R ^a   Li, Cheng ^a   Allam, Charles K ^a   Venuta, Salvatore ^b   Anderson, Kenneth C ^a   Munshi, Nikhil C ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c IMMUNOGEN INC   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CYTOTOXIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUN901; N2' DEACETYL N2' (3 MERCAPTO 1 OXOPROPYL)MAYTANSINE; NERVE CELL ADHESION MOLECULE; PARAPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; MIXED CELL CULTURE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SCID MOUSE; TUMOR XENOGRAFT; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD56; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; HUMANS; IMMUNOTOXINS; MALE; MAYTANSINE; MICE; MICE, SCID; MULTIPLE MYELOMA; NEURAL CELL ADHESION MOLECULES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3042822264     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0142     Document Type: Article

References (48)

1. Carter P. Improving the efficacy of antibody-antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
2. Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 2001;19:833-41.
3. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
4. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.
5. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001;40:17-24.
6. Farah RA, Clinchy B, Herrera L, Vitetta ES. The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryotic Gene Expression 1998;8: 321-56.
7. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993;261:212-5.
8. Kanellos J, Pietersz GA, McKenzie IF. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. J Natl Cancer Inst (Bethesda) 1985;75:319-32.
9. Starling JJ, Maciak RS, Law KL, et al. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes. Cancer Res 1991;51:2965-72.
10. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta 1997;1333:C1-6.
11. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6.
12. Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody- calicheamicin conjugate for treatment of acute myeloid leukemia: choice of linker. Bioconjug Chem 2002;13:40-6.
13. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001;41: 1206-14.
14. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975;189:1002-5.
15. Chabner BA, Levine AS, Johnson BL, Young RC. Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep 1978;62:429-33.
16. Blum RH, Kahlert T. Maytansine: a Phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 1978;62:435-8.
17. Cabanillas F, Rodriguez V, Hall SW, Burgess MA, Bodey GP, Freireich EJ. Phase I study of maytansine using a 3-day schedule. Cancer Treat Rep 1978;62:425-8.
18. Issell BF, Crooke ST. Maytansine. Cancer Treat Rev 1978;5:199-207.
19. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
20. Haglund C, Lindgren J, Roberts PJ, Kuusela P, Nordling S. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions: a comparison with CA 50 and CA 19-9. Br J Cancer 1989;60:845-51.
21. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996;93:8618-23.
22. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.
23. Thiery JP, Brackenbury R, Rutishauser U, Edelman GM. Adhesion among neural cells of the chick embryo. II. Purification and characterization of a cell adhesion molecule from neural retina. J Biol Chem 1977;252:6841-5.
24. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-6.
25. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 1986;164: 351-6.
26. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 1991;146:4421-6.
27. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983;130:2947-51.
28. Patel K, Moore SE, Dickson G, et al. Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. Int J Cancer 1989;44:573-8.
29. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658-63.
30. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997; 97:46-55.
31. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002;117:882-5.
32. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002;160:1293-9.
33. Pellat-Deceunynck C, Barille S, Puthier D, et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995;55:3647-53.
34. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998;12:1977-82.
35. Lust JA, Donovan KA. Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. Cancer Control 1998;5: 209-17.
36. Kaiser U, Auerbach B, Oldenburg M. The neural cell adhesion molecule NCAM in multiple myeloma. Leuk Lymphoma 1996;20:389-95.
37. Roguska MA, Pedersen JT, Keddy CA, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 1994;91: 969-73.
38. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
39. Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999;94: 701-12.
40. Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194:164-76.
41. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003; 97(Suppl):796-801.
42. Munshi NC, Hideshima T, Chauhan D, Richardson P, Anderson KC. Novel biologically based therapies for multiple myeloma. Int J Hematol 2002;76(Suppl 1):340-1.
43. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927-37.
44. Crossin KL, Chuong CM, Edelman GM. Expression sequences of cell adhesion molecules. Proc Natl Acad Sci USA 1985;82:6942-6.
45. Akeson RA, Wujek JR, Roe S, Warren SL, Small SJ. Smooth muscle cells transiently express NCAM. Brain Res 1988;464:107-20.
46. Smith S. Technology evaluation: C242-DM1, ImmunoGen Inc. Curr Opin Mol Ther 2001;3:198-203.
47. Epstein C, Lynch T, Shefner J, et al. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl 1994;8:57-9.
48. Lynch TJ Jr, Lambert JM, Coral F, et al. Immunotoxin therapy of small-cell lung cancer: a Phase I study of N901-blocked ricin. J Clin Oncol 1997;15:723-34.